Founded at the Abramson Cancer Center at the University of Pennsylvania

PC3I at ASH Annual Meeting and Exposition 2022

Visit ASH Website

 

Four Penn Center for Cancer Care Innovation (PC3I) Faculty will be presenting the latest advances in blood cancer research and treatment at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

 

2261. Overall Survival of Adult Acute Lymphoblastic Leukemia (ALL) Patients By Facility Volume and Type: A National Cancer Database Report

Kaitlyn C Dykes, MD, BS, Jiling Chou, MA, Allison Taylor, MD, MS, MA Xiaoyang, and Catherine Lai, MD
Poster Session: December 10, 17:30

 

668. Advanced Practice Providers (APPs) in Hematology: Work Practices, Interactions with Physicians, and Opportunities for Collaboration within the American Society of Hematology (ASH)

Leah E Masselink, PhD, Clese E Erikson, MPAff, Gina Moses, Faith E. Davies, MD, Azam Farooqui, MD, Peter A. Kouides, MD, Srikanth Nagalla, MBBS, MS, and Ariela L. Marshall, MD
Oral Session: December 11, 16:45

 

426. Real World Effectiveness of “7 + 3” Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia

Andrew Matthews, MD, Alexander E. Perl, MD, Selina M. Luger, MD, FRCPC, Saar Gill, MD, PhD, Catherine Lai, MD, David L. Porter, MD, Sarah Skuli, MD, PhD, Ximena Jordan Bruno, Craig W. Freyer, PharmD, Alison Carulli, PharmD, Martin P. Carroll, MD, Daria V. Babushok, MD, Noelle V. Frey, MD, MS, Elizabeth O. Hexner, MD, MSTR, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Edward A. Stadtmauer, MD, Alison W. Loren, MD, Vikram R Paralkar, MD, Ivan Maillard, MD, PhD, and Keith W. Pratz, MD
Oral Session: December 11, 10:45

 

983. CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Regina M. Myers, MD, Amanda M. DiNofia, MD, MSCE, Yimei Li, PhD, Caroline Diorio, MD, Richard Aplenc, MD, PhD, Diane Baniewicz, MSN, CRNP, Jennifer L Brogdon, PhD, Colleen Callahan, MSN, CRNP, Boris Engels, PhD, Joseph A. Fraietta, PhD, Vanessa Gonzalez, MBA, Emma Iannone, BS, Allison Barz Leahy, MD, MSCE, Hongyan Liu, PhD, Susan E. McClory, MD, PhD, Susan R. Rheingold, MD, Laura Shinehouse, BA, Gerald Wertheim, MD, PhD, Lisa Wray, MD, Noelle V. Frey, MD, MS, Shannon L. Maude, MD, PhD, and Stephan A. Grupp, MD, PhD
Oral Session: December 12, 17:30

 

4942. Influence of Household Income on Health-Related Quality of Life in Children with Acute Myeloid Leukemia

Haley Newman, MD, Yimei Li, PhD, Yuan-Shung V. Huang, MS, Caitlin W Elgarten, MD, MSCE, Regina M. Myers, MD, Jenny Ruiz, MD, Allison Barz Leahy, MD, MSCE, Catherine Aftandilian, MD, Staci D. Arnold, MD, MBA, MPH, Kira O Bona, MD, MPH, Mallorie M. Heneghan, MD, M Monica Gramatges, MD, PhD, Kelly W Maloney, MD, Arunkumar J. Modi, MD, Rajen Mody, MD, MS, Naomi J Winick, MD, Elaine Morgan, MD, Jennifer J. Wilkes, MD, MSCE, Alix E. Seif, MD, Brian T. Fisher, Richard Aplenc, MD, PhD, and Kelly D. Getz
Poster Session: December 12, 18:00

 

898. Barriers to Transition from Pediatric to Adult Care in Adolescents and Young Adults with Sickle Cell Disease: A Mixed-Method Study on the Impact of Systems of Inequity

Kemar V. Prussien, PhD, Haley L. Faust, BA, Kim Smith-Whitley, MD1, Lamia P. Barakat, PhD, and Lisa A. Schwartz, PhD
Oral Session: December 12, 15:30

 

4862. Fried’s Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Cristian C. Taborda, MD, Shannon H Gier, BS, Avery W Stivale, BS, Alexander E. Perl, MD, Saar Gill, MD, PhD, Daria V. Babushok, MD, Elizabeth O. Hexner, MD, MSTR, Noelle V. Frey, MD, MS, Catherine Lai, MD, Ximena Jordan Bruno, Mary Ellen Martin, MD, Ivan Maillard, MD, PhD, David L. Porter, MD, Alison W. Loren, MD, Keith W. Pratz, MD, Selina M. Luger, MD, FRCPC, Phyllis A. Gimotty, PhD, and Shannon R. McCurdy, MD
Poster Session: December 12, 18:00

 

4954. Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Ofir Wolach, Jacqueline S. Garcia, MD, Pinkal Desai, MD, MPH, Pankit Vachhani, MD, Joshua F. Zeidner, MD, Sameem Abedin, MD, Kendra Sweet, MD, Catherine Lai, MD, Yakir Moshe, MD, PhD, Daniel A. Pollyea, MD, Marin Xavier, Boaz Nachmias, Tsila Zuckerman, MD, Sangmin Lee, Evan C. Chen, Srilakshmi Bathini, MD, Wesleigh Edwards, Cat N. Bui, PharmD, Wei-Han Cheng, PhD, Catherine Miller, PharmD, Annie Guerin, Jessica Maitland, Esprit Ma, MPH, Melissa Montez, PharmD, Moshe Grunspan, and Aaron D Goldberg, MD, PhD
Poster Session: December 12, 18:00

 

Additionally, PC3I Faculty will serve as moderators of the following sessions: 

 

616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Relapsed/Refractory AML

Moderator: Catherine Lai.

Implications of the Aging Microenvironment

Moderator: Catherine Lai.

Related News